Key Takeaways
- United Therapeutics (UTHR) shares climbed approximately 13% following a favorable Delaware federal court decision in a patent infringement lawsuit.
- The court determined that Liquidia violated two specific patent claims related to inhaled treprostinil therapies.
- Liquidia (LQDA) stock plummeted more than 50% in response to the court’s decision.
- The judge has given both pharmaceutical companies seven days to file proposed remedies.
- UTHR shares are trading close to their 52-week peak and have gained roughly 10% year-to-date.
Shares of United Therapeutics (NASDAQ: UTHR) surged 13% on Wednesday following a federal court decision that sided with the biotechnology company in an extended patent litigation battle. The stock reached approximately $543.86 per share, approaching its 52-week peak of $596.76 established in May 2026.
United Therapeutics Corporation, UTHR
A U.S. District Court in Delaware determined that competitor Liquidia Corporation violated two patent claims owned by United Therapeutics. These claims relate to the use of inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease, including dry powder delivery systems.
In stark contrast, Liquidia’s stock collapsed by more than 50% during the same trading session.
Court Ruling Details
The Delaware court concluded that claims 1 and 14 from U.S. Patent No. 11,826,327 were both enforceable and violated by Liquidia’s Yutrepia inhalation powder product. The remaining four claims that United Therapeutics presented in the litigation were deemed invalid by the court.
The judge has given both pharmaceutical companies a seven-day window to present proposed legal remedies. United Therapeutics has already requested injunctive relief through its post-trial submissions. Such an injunction could significantly restrict Liquidia’s ability to market and distribute Yutrepia.
The FDA granted approval for Yutrepia in 2025 for treating both pulmonary arterial hypertension and PH-ILD. United Therapeutics initiated the legal action under the Hatch-Waxman Act, which provides a framework for resolving patent conflicts between branded pharmaceutical companies and generic drug manufacturers.
Liquidia’s Statement
Roger Jeffs, CEO of Liquidia, expressed the company’s disagreement with the court’s findings on claims 1 and 14. He stated that Liquidia will move forward with an appellate challenge to the decision.
Jeffs further indicated that Liquidia will file a supplemental submission to Yutrepia’s New Drug Application. This action would aim to completely eliminate the PH-ILD indication from the medication’s approved labeling.
Liquidia acknowledged it cannot accurately project the financial consequences of this ruling at present. The company cited numerous uncertainties, including the outcome of appeals and additional legal proceedings that remain pending.
Potential scenarios include anything from a more restricted label for Yutrepia to comprehensive constraints on the product’s commercial distribution.
This isn’t the only notable price movement for United Therapeutics stock in recent weeks. Less than a week before this surge, shares declined 4% after Goldman Sachs analyst Andrea Newkirk initiated coverage with a Sell recommendation.
Significant single-day volatility is uncommon for United Therapeutics shares. The stock has experienced daily moves exceeding 5% only five times in the last twelve months, making this week’s 13% gain particularly noteworthy.
Year-to-date, the stock has appreciated approximately 10%. Long-term investors who allocated $1,000 to United Therapeutics five years ago would currently hold a position valued at around $2,947.
The legal proceedings now advance to the remedies phase, with submissions from both parties expected within seven days.
The post United Therapeutics (UTHR) Stock Soars 13% Following Major Patent Infringement Victory appeared first on Blockonomi.
